<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03980093</url>
  </required_header>
  <id_info>
    <org_study_id>18-0234</org_study_id>
    <nct_id>NCT03980093</nct_id>
  </id_info>
  <brief_title>The REACH Study: A Novel Values-Based Intervention to Increase Endocrine Therapy Adherence Among Breast Cancer Survivors</brief_title>
  <official_title>A Novel Values-Based Intervention to Increase Endocrine Therapy Adherence Among Breast Cancer Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Boulder</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Boulder</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot trial compares two online interventions to improve adherence to anti-hormonal
      medication among women with the most common form of breast cancer (estrogen
      receptor-positive).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Medication adherence assessed by electronic pillbox (Wisepill box)</measure>
    <time_frame>Change from baseline through 6 month follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self-reported medication adherence</measure>
    <time_frame>Change from baseline to 3 and 6 month follow-up</time_frame>
    <description>Reported anti-hormonal medication pills missed, past 30 days, with a validated self-reported medication adherence item</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and negative emotional associations with taking anti-hormonal medication</measure>
    <time_frame>Change from baseline through 6 month follow-up</time_frame>
    <description>Emotional Attitudes Scale, adapted to focus on anti-hormonal medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intentions to adhere to anti-hormonal medication in the next year and next several years</measure>
    <time_frame>Change from baseline through 6 month follow up</time_frame>
    <description>Anti-Hormonal Medication Intentions Scale (average score on a 1 to 7 scale; higher=better outcome, e.g., stronger intentions to adhere), adapted from the Health Behavior Intentions Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication nonpersistence assessed by electronic pillbox (Wisepill box)</measure>
    <time_frame>Baseline through 6 month follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Education plus Values</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Education</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Education</intervention_name>
    <description>Online medical education on the benefits of anti-hormonal medication, potential side effects, and how to manage them.</description>
    <arm_group_label>Education</arm_group_label>
    <arm_group_label>Education plus Values</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Values</intervention_name>
    <description>An Acceptance and Commitment Therapy (ACT)-based intervention consisting of brief online sessions plus a visual cue-based intervention focused on personal values.</description>
    <arm_group_label>Education plus Values</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria include:

          1. Women in Colorado treated for Stage 0 to III estrogen receptor-positive breast cancer
             who have completed primary cancer treatment (surgery, chemotherapy, and/or radiation)
             and within the past 2.5 years, have been prescribed anti-hormonal therapy

          2. Take their anti-hormonal therapy medication at least occasionally and have at least 1
             more year left on their prescription

          3. Report at least 1 factor that makes taking their anti-hormonal therapy medication
             difficult

          4. Have internet access
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanna J Arch, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Boulder</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Greenwood Village</city>
        <state>Colorado</state>
        <zip>80111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 29, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Colorado, Boulder</investigator_affiliation>
    <investigator_full_name>Joanna Arch</investigator_full_name>
    <investigator_title>Associate Professor, Department of Psychology and Neuroscience</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

